Full-Time

Associate Director

Commercial Data Management

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$209k - $231kAnnually

Senior

San Bruno, CA, USA

Requires onsite presence in South San Francisco for at least 3 days a week.

Category
Data Management
Data Analysis
Data & Analytics
Required Skills
SQL
Tableau
Data Analysis
Requirements
  • Bachelor's degree in computer science, data science, or a related field is required
  • 7+ years of biotech or pharma experience in IT, analytics, and/or data management
  • Expertise with standard pharmaceutical data sources (such as Rx, HCP/HCO demographics, formulary, CRM, CLM, etc.) required
  • Experience with MDM concepts and platforms and SQL-based data warehouse design
  • Experience with Tableau, Alteryx, and/or other BI tools
  • Experience with omnichannel marketing data and AI-driven analytics a plus
  • Knowledge of data management capabilities (data governance, data quality, metadata management, master data management, data lifecycle management, and data lineage)
  • Experience in product launch and/or establishing new data environments
  • Shown success in directing and managing multiple external vendors
  • Excellent project management skills, including the ability to lead in an environment with multiple partners and contending priorities
  • Good interpersonal and communication skills, including the ability to translate business requirements into technical requirements and the ability to communicate complex technology concepts to commercial partners and end-users in a manner that ties to their business objectives
  • Proven commitment to excellence and continuous improvement
  • Ability to work cross-functionally in a team-based environment, including external vendors while fostering a culture that is reflective of Cytokinetics’ values
  • Ability to plan, coordinate, and complete multiple projects efficiently, on time, and within budget in an environment of challenging and changing priorities
  • Business travel, by air or car, is required for internal and external business meetings
  • Ability to work onsite in South San Francisco at least 3 days a week
  • Compliance with all laws, regulations, policies, and procedures that govern the conduct of Cytokinetics activities
Responsibilities
  • Lead with curiosity, plan, and execute commercial data and analytics initiatives in close collaboration with IT and commercial stakeholders.
  • Maintain a Commercial Data Map, recording the location and use of each data source used by the Commercial team.
  • Manage and provide direction to the vendor managing the Commercial Data Warehouse, Master Data Management (MDM), and data and analytics ecosystem.
  • Establish and manage BI technical processes to ensure that reports and dashboards are produced on schedule.
  • Lead data onboarding and data warehouse enhancement projects, including integration of CRM data.
  • Working with the analytics team and supporting vendors, create and manage the roadmap for enhancements to our data architecture and analytics capabilities.
  • Responsible for planning, budgeting, contracting, and accrual activities related to the Commercial Data and Analytics environments and initiatives.
  • Taking initiative and partnering with Commercial Analytics and Field Operations, lead and improve Cytokinetics’ data and data management ecosystem.
  • Brings critical thinking, and organized skills with an emphasis on a business partner-centric mindset.
  • Executes initiatives and follows up with stakeholders to ensure project or operational activities are scheduled and completed on time.
  • Together with vendor partners, enable data stewardship that meets business needs.
  • Identify, evaluate, and maintain relationships with best-in-class vendors.
  • Develop, implement, and manage processes, in partnership with the Commercial department, that follow all applicable laws (e.g., HIPAA) and Cytokinetics’ policies.
  • Know the latest data and analytics techniques and capabilities, leading the implementation of new capabilities and standard methodologies.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?